Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
AbCellera Biologics Inc. - Common Shares
(NQ:
ABCL
)
11.67
+0.26 (+2.28%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,586,380
Open
11.44
Bid (Size)
11.50 (200)
Ask (Size)
11.70 (100)
Prev. Close
11.41
Today's Range
11.18 - 11.73
52wk Range
2.745 - 12.58
Shares Outstanding
287,686,199
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
Today 16:05 EDT
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
September 02, 2026
From
AbCellera Biologics Inc.
Via
Business Wire
Performance
YTD
+240.2%
+240.2%
1 Month
+4.2%
+4.2%
3 Month
+129.3%
+129.3%
6 Month
+228.7%
+228.7%
1 Year
+168.3%
+168.3%
More News
Read More
Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
August 19, 2026
From
USA News Group
Via
GlobeNewswire
AbCellera Biologics (NASDAQ:ABCL) Misses Q2 Estimates, Falls Short on Revenue and EPS
↗
August 05, 2026
Via
Chartmill
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
August 13, 2026
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera (ABCL) Q2 2026 Earnings Call Transcript
↗
August 12, 2026
Via
The Motley Fool
Topics
Earnings
Intellectual Property
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
August 11, 2026
From
AbCellera Biologics Inc.
Via
Business Wire
Here are the top movers in Monday's session.
↗
August 10, 2026
Via
Chartmill
There are notable gap-ups and gap-downs in today's session.
↗
August 10, 2026
Via
Chartmill
AI Found an Influenza Target That Survives Viral Mutation
August 10, 2026
From
Equity Insider
Via
GlobeNewswire
AbCellera’s ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial
↗
August 10, 2026
Via
MarketBeat
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile
August 10, 2026
From
AbCellera Biologics Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
↗
August 07, 2026
Via
Benzinga
Get insights into the top gainers and losers of Friday's after-hours session.
↗
August 07, 2026
Via
Chartmill
AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026
August 07, 2026
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Biologics Q2 Earnings Call Highlights
↗
August 05, 2026
Via
MarketBeat
Topics
Earnings
AbCellera Reports Q2 2026 Business Results
August 05, 2026
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
July 29, 2026
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026
July 07, 2026
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Appoints Dr. Lynn Seely to its Board of Directors
July 06, 2026
From
AbCellera Biologics Inc.
Via
Business Wire
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
June 17, 2026
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Appoints Dr. Victor Sandor to its Board of Directors
June 05, 2026
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Biologics Bets on Hot Flash Antibody as Pipeline Pivot Gains Steam
↗
June 04, 2026
Via
MarketBeat
AbCellera Biologics Q1 Earnings Call Highlights
↗
May 11, 2026
Via
MarketBeat
Topics
Earnings
AbCellera (ABCL) Q1 2026 Earnings Transcript
↗
May 11, 2026
Via
The Motley Fool
Topics
Intellectual Property
Frequently Asked Questions
Is AbCellera Biologics Inc. - Common Shares publicly traded?
Yes, AbCellera Biologics Inc. - Common Shares is publicly traded.
What exchange does AbCellera Biologics Inc. - Common Shares trade on?
AbCellera Biologics Inc. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for AbCellera Biologics Inc. - Common Shares?
The ticker symbol for AbCellera Biologics Inc. - Common Shares is ABCL on the Nasdaq Stock Market
What is the current price of AbCellera Biologics Inc. - Common Shares?
The current price of AbCellera Biologics Inc. - Common Shares is 11.67
When was AbCellera Biologics Inc. - Common Shares last traded?
The last trade of AbCellera Biologics Inc. - Common Shares was at 09/16/26 04:00 PM ET
What is the market capitalization of AbCellera Biologics Inc. - Common Shares?
The market capitalization of AbCellera Biologics Inc. - Common Shares is 3.36B
How many shares of AbCellera Biologics Inc. - Common Shares are outstanding?
AbCellera Biologics Inc. - Common Shares has 3B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
